Skip to main content

High-Dose Intravitreal Topotecan for Refractory or Recurrent Retinoblastoma: Efficacy, Safety and Intraocular Cytokine Profiles

In brief

High-dose topotecan preserved 93% of eyes with recurrent retinoblastoma

In a prospective case series of 15 eyes with refractory or recurrent retinoblastoma, high-dose intravitreal topotecan controlled intraocular seeds in every eye and preserved 14 of 15 eyes after a median nine months of follow-up. Retinal function remained stable and no severe adverse events were reported, but the small, noncomparative study leaves longer-term effectiveness uncertain.

Journal
American journal of ophthalmology (Q1)
Published
10 November 2026
Study design
Case series / case report
Evidence level
Level 4, Very Low (CEBM 4)
Authors
Xintong Lin, Zhuqing Zheng, Haifeng Chen, Jiang Qian, Qiang Liu, Ruiqi Ma, et al.
PMID
43009085
DOI
10.1016/j.ajo.2026.11.002

Why clinicians should know about it

  • Picked for Ophthalmology (paper of the day, 15 November 2026): Intravitreal therapy, retinal function, and globe salvage in retinoblastoma

Abstract

OBJECTIVE: To evaluate the outcomes and safety of high-dose intravitreal topotecan (100 μg, IVitT100) in the treatment of refractory or recurrent intraocular retinoblastoma (RB). DESIGN: Prospective, non-comparative case series. PARTICIPANTS: 15 consecutive patients (15 eyes) with refractory or recurrent RB at the Eye & ENT Hospital of Fudan University between October 2023 and September 2025. METHODS: Participants received IVitT100 every four weeks. Clinical characteristics were recorded before and after treatment. Tumor control and injection-related complications were assessed at each visit. Aqueous humor cytokines and electroretinography (ERG) were analyzed to evaluate inflammatory changes and retinal function. MAIN OUTCOME MEASURES: Treatment outcomes, including intraretinal tumor and intraocular seeds control, globe salvage rate, and ocular and systemic adverse events, were assessed during follow-up. RESULTS: At a median follow-up of 9 months (IQR, 6.0-14.0) after the final intravitreal injection, high-dose intravitreal topotecan achieved a globe salvage rate of 93%, with complete control of intraocular seeds in all eyes (100%) and complete regression of intraretinal tumors in 3 of 4 eyes (75%). Baseline ERG amplitude was 5.7 μV (IQR, 1.5-14.7), post-treatment amplitude was 5.7 μV (IQR, 1.9-15.8), showing no significant retinal function impairment (P = 0.429). None of the 27 cytokines showed significant changes between pre- and post-treatment measurements in RB eyes (all P > 0.05). No severe ocular or systemic adverse events were reported. CONCLUSIONS: IVitT100 is highly effective for refractory or recurrent RB with vitreous seeds, subretinal seeds, and intraretinal tumors. It exhibits minimal retinal toxicity and does not induce intraocular inflammatory responses, supporting its role as a safe and effective first-line intravitreal therapy for advanced RB.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.